Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease


Study Number
734920
Phase
II
Age Group
Adult
Purpose

This phase II trial studies how well acalabrutinib works in treating patients with chronic graft versus host disease. Acalabrutinib may be an effective treatment for graft-versus-host disease caused by a stem cell transplant.

Full Title

Acalabrutinib for chronic graft versus host disease

ClinicalTrials.Gov ID
NCT04198922

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.